Pfizer
INFLECTRA
Manufacturer:
Pfizer
Name:
INFLECTRA
HCPCS Code Descriptor:
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Category:
Q Code
HCPCS:
Q5103
NDC(s):
00069-0809-01
Primary Type:
Immunology Anti-TNF Biosimilar
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
INFLECTRA is an Immunology Anti-TNF Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5103 is aligned to the drug INFLECTRA.
Inflectra (infliximab) is a monoclonal antibody and is used to treat a range of inflammatory autoimmune disorders. Inflectra binds to tumor necrosis factor-alpha and prevents it from activating certain processes. This drug is administered via a 2-hour intravenous infusion. Inflectra is manufactured by Pfizer and is a biosimilar to Remicade (J1745). Inflectra was aligned to the Q Code: Q5102 until March 2018, when it was realigned to the Q Code: Q5103. Patient Assistance can be found through the Pfizer EnCompass program.
Access Pricing and More By Registering
HCPCS Added Date:
4/1/18
HCPCS Effective Date:
4/1/18
HCPCS Short Description:
Injection, inflectra
Billing and Coding Guide:
https://www.pfizerencompassresources.com/sites/default/files/ifa-billing_and_coding_guide_for_inflectra.pdf
Patient Assistance:
https://www.pfizerencompass.com/